Hamlet Gasoyan, PhD

Conversations between the patient and provider should focus on the stakes of antiobesity treatment and continuation, says Hamlet Gasoyan, PhD, Cleveland Clinic.

In a Cleveland Clinic cohort, patients who stopped treatment for obesity had smaller weight losses to start, making these gains easier to maintain, explained Hamlet Gasoyan, PhD.

Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.

Real-world cost barriers and insurance denials contribute to early discontinuation of injectable glucagon-like peptide-1 (GLP-1) receptor agonists, reducing their effectiveness for weight loss, explains Hamlet Gasoyan, PhD, Cleveland Clinic.